NLS Pharmaceutics announced that the Patents Registry, Intellectual Property Department of The Government of the Hong Kong Special Administrative Region has granted approval for Patent Application 42022055879.5, which covers Mazindol ER as a method of treatment for ADHD. This patent is expected to expire no earlier than 2037.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NLSP:
- NLS Pharmaceutics CEO says proprietary position on Quilience ‘is strong’
- NLS Pharmaceutics announces Israeli patent grant for Mazindol
- NLS Pharmaceutics closes initial tranche of $10M purchase agreement
- NLS Pharmaceutics upgraded to Buy from Hold at Maxim
- NLS Pharmaceutics announces purchase agreement with BVF Partners